Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT…

Overview of attention for article published in Annals of Oncology, October 2025

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (78th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

blogs: 1 blog

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 1 blog post.

Rucaparib monotherapy provides long-term benefit as first-line maintenance for patients with advanced ovarian cancer with and without HRD

Grey Horizon, 07 Nov 2025

Results of ATHENA-MONO/GOG-3020/ENGOT-ov45, a phase III trial investigating rucaparib as a monotherapy in first-line…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.